260 related articles for article (PubMed ID: 21068376)
1. Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy.
Doles J; Oliver TG; Cameron ER; Hsu G; Jacks T; Walker GC; Hemann MT
Proc Natl Acad Sci U S A; 2010 Nov; 107(48):20786-91. PubMed ID: 21068376
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
3. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance.
Lin X; Howell SB
Mol Cancer Ther; 2006 May; 5(5):1239-47. PubMed ID: 16731756
[TBL] [Abstract][Full Text] [Related]
4. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer.
Vassel FM; Bian K; Walker GC; Hemann MT
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28922-28924. PubMed ID: 33144509
[TBL] [Abstract][Full Text] [Related]
5. Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner.
Jokić M; Vlašić I; Rinneburger M; Klümper N; Spiro J; Vogel W; Offermann A; Kümpers C; Fritz C; Schmitt A; Riabinska A; Wittersheim M; Michels S; Ozretić L; Florin A; Welcker D; Akyuz MD; Nowak M; Erkel M; Wolf J; Büttner R; Schumacher B; Thomale J; Persigehl T; Maintz D; Perner S; Reinhardt HC
Mol Cancer Res; 2016 Nov; 14(11):1110-1123. PubMed ID: 27514406
[TBL] [Abstract][Full Text] [Related]
6. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA‑29a enhances cisplatin sensitivity in non‑small cell lung cancer through the regulation of REV3L.
Chen X; Zhu H; Ye W; Cui Y; Chen M
Mol Med Rep; 2019 Feb; 19(2):831-840. PubMed ID: 30535450
[TBL] [Abstract][Full Text] [Related]
8. Glutamate-cysteine ligase catalytic subunit is associated with cisplatin resistance in lung adenocarcinoma.
Hiyama N; Ando T; Maemura K; Sakatani T; Amano Y; Watanabe K; Kage H; Yatomi Y; Nagase T; Nakajima J; Takai D
Jpn J Clin Oncol; 2018 Apr; 48(4):303-307. PubMed ID: 29474642
[TBL] [Abstract][Full Text] [Related]
9. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
10. Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival.
Dai CH; Chen P; Li J; Lan T; Chen YC; Qian H; Chen K; Li MY
Oncotarget; 2016 Oct; 7(40):65157-65170. PubMed ID: 27533083
[TBL] [Abstract][Full Text] [Related]
11. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair.
Lin X; Trang J; Okuda T; Howell SB
Clin Cancer Res; 2006 Jan; 12(2):563-8. PubMed ID: 16428501
[TBL] [Abstract][Full Text] [Related]
12. Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress.
Kotov IN; Siebring-van Olst E; Knobel PA; van der Meulen-Muileman IH; Felley-Bosco E; van Beusechem VW; Smit EF; Stahel RA; Marti TM
Mol Oncol; 2014 Dec; 8(8):1747-59. PubMed ID: 25113059
[TBL] [Abstract][Full Text] [Related]
13. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
14. Immortalized mouse cell lines that lack a functional Rev3 gene are hypersensitive to UV irradiation and cisplatin treatment.
Zander L; Bemark M
DNA Repair (Amst); 2004 Jul; 3(7):743-52. PubMed ID: 15177183
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
16. A PolH Transcript with a Short 3'UTR Enhances PolH Expression and Mediates Cisplatin Resistance.
Zhang J; Sun W; Ren C; Kong X; Yan W; Chen X
Cancer Res; 2019 Jul; 79(14):3714-3724. PubMed ID: 31064846
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
18. Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.
Sangodkar J; DiFeo A; Feld L; Bromberg R; Schwartz R; Huang F; Terzo EA; Choudhri A; Narla G
Lung Cancer; 2009 Dec; 66(3):292-7. PubMed ID: 19328586
[TBL] [Abstract][Full Text] [Related]
19. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
Gomes LR; Rocha CRR; Martins DJ; Fiore APZP; Kinker GS; Bruni-Cardoso A; Menck CFM
Cell Death Dis; 2019 Jun; 10(6):459. PubMed ID: 31189884
[TBL] [Abstract][Full Text] [Related]
20. Absence of REV3L promotes p53-regulated cancer cell metabolism in cisplatin-treated lung carcinoma cells.
Kong L; Murata MM; Digman MA
Biochem Biophys Res Commun; 2018 Jan; 496(1):199-204. PubMed ID: 29307819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]